Suppr超能文献

D-二聚体——正常水平与因多种情况导致的升高水平,包括“D-二聚体血症”、炎症、血栓栓塞、弥散性血管内凝血和 COVID-19。

D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, Including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19.

机构信息

Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom.

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.

出版信息

Semin Thromb Hemost. 2022 Sep;48(6):672-679. doi: 10.1055/s-0042-1748193. Epub 2022 Jul 8.

Abstract

D-dimers reflect a breakdown product of fibrin. The current narrative review outlines how D-dimers can arise in normal individuals, as well as in patients suffering from a wide range of disease states. D-dimers in normal individuals without evident thrombosis can arise from background fibrinolytic activity in various tissues, including kidney, mammary and salivary glands, which ensures smooth flow of arising fluids where any blood contamination could be immediately lysed. In addition, healthy individuals can also regularly sustain minor injuries, often unbeknown to them, and wound healing follows clot formation in these situations. D-dimers can also arise in anxiety and following exercise, and are also markers of inflammation. Lung inflammation (triggered by microbes or foreign particles) is perhaps also particularly relevant, since the hemostasis system and fibrinolysis help to trap and remove such debris. Lung inflammation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may contribute to D-dimer levels additive to thrombosis in patients with COVID-19 (coronavirus disease 2019). Indeed, severe COVID-19 can lead to multiple activation events, including inflammation, primary and secondary hemostasis, and fibrinolysis, all of which may contribute to cumulative D-dimer development. Finally, D-dimer testing has also found a role in the diagnosis and triaging of the so-called (COVID-19) vaccine-induced thrombotic thrombocytopenia.

摘要

D-二聚体反映了纤维蛋白的分解产物。目前的叙述性综述概述了 D-二聚体如何在正常个体以及患有广泛疾病状态的患者中产生。在没有明显血栓形成的正常个体中,D-二聚体可能来自各种组织中的背景纤维蛋白溶解活性,包括肾脏、乳腺和唾液腺,这可确保任何血液污染的液体顺畅流动并立即被溶解。此外,健康个体也可能经常遭受他们不知道的轻微损伤,在这些情况下,伤口愈合会跟随血栓形成。D-二聚体也会在焦虑和运动后产生,并且也是炎症的标志物。肺部炎症(由微生物或异物颗粒引发)可能也特别相关,因为止血系统和纤维蛋白溶解有助于捕获和清除这些碎片。严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 患者的肺部炎症可能导致 COVID-19(2019 年冠状病毒病)患者的 D-二聚体水平与血栓形成相加。事实上,严重的 COVID-19 可能导致多种激活事件,包括炎症、原发性和继发性止血以及纤维蛋白溶解,所有这些都可能导致累积的 D-二聚体发展。最后,D-二聚体检测也在所谓的(COVID-19)疫苗诱导的血栓性血小板减少症的诊断和分诊中找到了作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验